{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:44Z","timestamp":1793228264007,"version":"4.5.0"},"reference-count":196,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sotio Biotech"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is among the top five causes of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant cells to the peritoneum. Despite improvements in medical therapies, particularly with the implementation of novel drugs targeting homologous recombination deficiency, the survival rates of patients with EOC remain low. Unlike other neoplasms, EOC remains relatively insensitive to immune checkpoint inhibitors, which is correlated with a tumor microenvironment (TME) characterized by poor infiltration by immune cells and active immunosuppression dominated by immune components with tumor-promoting properties, especially tumor-associated macrophages (TAMs). In recent years, TAMs have attracted interest as potential therapeutic targets by seeking to reverse the immunosuppression in the TME and enhance the clinical efficacy of immunotherapy. Here, we review the key biological features of TAMs that affect tumor progression and their relevance as potential targets for treating EOC. We especially focus on the therapies that might modulate the recruitment, polarization, survival, and functional properties of TAMs in the TME of EOC that can be harnessed to develop superior combinatorial regimens with immunotherapy for the clinical care of patients with EOC.<\/jats:p>","DOI":"10.1136\/jitc-2022-005968","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T09:25:19Z","timestamp":1677144319000},"page":"e005968","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":70,"title":["Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02477644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760797","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02718911","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01525602","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02452424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02923739","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02526017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00537368","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01204996","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01248949","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01493505","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01688206","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04691375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00319748","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01294293","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01666444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00319748","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01666444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01666444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02554812","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02637531","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03719326","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00607048","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02665416","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03329950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05231122","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02480374","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03393884","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04660929","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03834948","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02216409","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03558139","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02953782","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03990233","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01685255","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02575807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02734004","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02484404","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02484404","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03737643","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Iva","family":"Truxova","sequence":"first","affiliation":[{"name":"Sotio Biotech, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":false,"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Spisek","sequence":"additional","affiliation":[{"name":"Sotio Biotech, Prague, Czech Republic"},{"name":"Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-479X","authenticated-orcid":false,"given":"Jitka","family":"Fucikova","sequence":"additional","affiliation":[{"name":"Sotio Biotech, Prague, Czech Republic"},{"name":"Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2025100308440577000_11.2.e005968.1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological configuration of ovarian carcinoma: features and impact on disease outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.trecan.2022.01.010","article-title":"Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents","volume":"8","author":"Fucikova","year":"2022","journal-title":"Trends Cancer"},{"key":"2025100308440577000_11.2.e005968.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100308440577000_11.2.e005968.4","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100105"},{"key":"2025100308440577000_11.2.e005968.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4019"},{"key":"2025100308440577000_11.2.e005968.6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.ircmb.2020.01.005","article-title":"Links between cancer metabolism and cisplatin resistance","volume":"354","author":"Cocetta","year":"2020","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308440577000_11.2.e005968.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5"},{"key":"2025100308440577000_11.2.e005968.8","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100308440577000_11.2.e005968.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"2025100308440577000_11.2.e005968.10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/bs.ircmb.2021.06.003","article-title":"DNA double-strand break repair in cancer: A path to achieving precision medicine","volume":"364","author":"Gillyard","year":"2021","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308440577000_11.2.e005968.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0076-6"},{"key":"2025100308440577000_11.2.e005968.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"2025100308440577000_11.2.e005968.13","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12766"},{"key":"2025100308440577000_11.2.e005968.14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308440577000_11.2.e005968.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"2025100308440577000_11.2.e005968.16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers13246231","article-title":"Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment","volume":"13","author":"Johnson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100308440577000_11.2.e005968.17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2019","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"2025100308440577000_11.2.e005968.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025100308440577000_11.2.e005968.20","doi-asserted-by":"crossref","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep"},{"key":"2025100308440577000_11.2.e005968.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.008"},{"key":"2025100308440577000_11.2.e005968.22","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12236"},{"key":"2025100308440577000_11.2.e005968.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.010"},{"key":"2025100308440577000_11.2.e005968.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.014"},{"key":"2025100308440577000_11.2.e005968.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1"},{"key":"2025100308440577000_11.2.e005968.26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00137","article-title":"Tumor-Associated macrophages contribute to tumor progression in ovarian cancer","volume":"4","author":"Colvin","year":"2014","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17030320","article-title":"CD86(+)\/CD206(+), diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis","volume":"17","author":"Dong","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025100308440577000_11.2.e005968.28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4048\/jbc.2019.22.e5","article-title":"Tumor-Associated macrophages as potential prognostic biomarkers of invasive breast cancer","volume":"22","author":"Jeong","year":"2019","journal-title":"J Breast Cancer"},{"key":"2025100308440577000_11.2.e005968.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2009.02369.x"},{"key":"2025100308440577000_11.2.e005968.30","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","article-title":"Single-Cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100308440577000_11.2.e005968.31","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211066245","article-title":"Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer","volume":"49","author":"Zhang","year":"2021","journal-title":"J Int Med Res"},{"key":"2025100308440577000_11.2.e005968.32","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040960","article-title":"Tissue-Resident and recruited macrophages in primary tumor and metastatic microenvironments: potential targets in cancer therapy","volume":"10","author":"Cotechini","year":"2021","journal-title":"Cells"},{"key":"2025100308440577000_11.2.e005968.33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.788365","article-title":"Tumor associated macrophages: origin, recruitment, phenotypic diversity, and targeting","volume":"11","author":"Hourani","year":"2021","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.34","doi-asserted-by":"crossref","first-page":"109539","DOI":"10.1016\/j.cellsig.2020.109539","article-title":"Gata3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma","volume":"68","author":"El-Arabey","year":"2020","journal-title":"Cell Signal"},{"key":"2025100308440577000_11.2.e005968.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000979","article-title":"M2-Like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer","volume":"8","author":"Hensler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01652.x"},{"key":"2025100308440577000_11.2.e005968.37","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-4-30","article-title":"Monocyte\/Macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease","volume":"4","author":"Wang","year":"2006","journal-title":"J Transl Med"},{"key":"2025100308440577000_11.2.e005968.38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","article-title":"Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis","volume":"147","author":"Yuan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2438-8","article-title":"Tumor-Associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (Tgfbi) and tenascin C","volume":"11","author":"Steitz","year":"2020","journal-title":"Cell Death Dis"},{"key":"2025100308440577000_11.2.e005968.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87252"},{"key":"2025100308440577000_11.2.e005968.41","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01246-z","article-title":"Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1","volume":"3","author":"Krishnan","year":"2020","journal-title":"Commun Biol"},{"key":"2025100308440577000_11.2.e005968.42","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.7314\/APJCP.2013.14.10.5883","article-title":"Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer","volume":"14","author":"Chen","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025100308440577000_11.2.e005968.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072587"},{"key":"2025100308440577000_11.2.e005968.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(02)02302-5"},{"key":"2025100308440577000_11.2.e005968.45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117933"},{"key":"2025100308440577000_11.2.e005968.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.785"},{"key":"2025100308440577000_11.2.e005968.47","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/cas.13567","article-title":"Cross-Talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment","volume":"109","author":"Tang","year":"2018","journal-title":"Cancer Sci"},{"key":"2025100308440577000_11.2.e005968.48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cancers14215224","article-title":"Metabolic reprogramming in tumor-associated macrophages in the ovarian tumor microenvironment","volume":"14","author":"Kumar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100308440577000_11.2.e005968.49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061411","article-title":"Transcriptional, epigenetic and metabolic programming of tumor-associated macrophages","volume":"12","author":"Larionova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100308440577000_11.2.e005968.50","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2019.52.6.140"},{"key":"2025100308440577000_11.2.e005968.51","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490"},{"key":"2025100308440577000_11.2.e005968.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00154-5"},{"key":"2025100308440577000_11.2.e005968.53","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.85"},{"key":"2025100308440577000_11.2.e005968.54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3826"},{"key":"2025100308440577000_11.2.e005968.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.02.016"},{"key":"2025100308440577000_11.2.e005968.56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102401","article-title":"The crowded crosstalk between cancer cells and stromal microenvironment in gynecological malignancies: biological pathways and therapeutic implication","volume":"20","author":"De Nola","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025100308440577000_11.2.e005968.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.054"},{"key":"2025100308440577000_11.2.e005968.58","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"2025100308440577000_11.2.e005968.59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1196"},{"key":"2025100308440577000_11.2.e005968.60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0536"},{"key":"2025100308440577000_11.2.e005968.61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00120","article-title":"Macrophages\/Microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brain","volume":"11","author":"Herrera-Rios","year":"2020","journal-title":"Front Immunol"},{"key":"2025100308440577000_11.2.e005968.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.01.012"},{"key":"2025100308440577000_11.2.e005968.63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0465"},{"key":"2025100308440577000_11.2.e005968.64","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141115","article-title":"Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis","volume":"5","author":"Xia","year":"2020","journal-title":"JCI Insight"},{"key":"2025100308440577000_11.2.e005968.65","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10979-3","article-title":"Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma","volume":"10","author":"Czystowska-Kuzmicz","year":"2019","journal-title":"Nat Commun"},{"key":"2025100308440577000_11.2.e005968.66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ygyno.2016.12.021","article-title":"Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: a comparison of matched primary and metastatic tumors","volume":"144","author":"Gottlieb","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1866"},{"key":"2025100308440577000_11.2.e005968.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00152-3"},{"key":"2025100308440577000_11.2.e005968.69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0479"},{"key":"2025100308440577000_11.2.e005968.70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0912"},{"key":"2025100308440577000_11.2.e005968.71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/ol.2016.5428","article-title":"Differential distribution of tumor-associated macrophages and treg\/th17 cells in the progression of malignant and benign epithelial ovarian tumors","volume":"13","author":"Zhu","year":"2017","journal-title":"Oncol Lett"},{"key":"2025100308440577000_11.2.e005968.72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3373"},{"key":"2025100308440577000_11.2.e005968.73","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/bjc.2017.297","article-title":"Crosstalk between tems and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer","volume":"117","author":"Wang","year":"2017","journal-title":"Br J Cancer"},{"key":"2025100308440577000_11.2.e005968.74","doi-asserted-by":"crossref","first-page":"106471","DOI":"10.1016\/j.intimp.2020.106471","article-title":"Tumor associated macrophages in the molecular pathogenesis of ovarian cancer","volume":"84","author":"Yousefzadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2025100308440577000_11.2.e005968.75","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0497-3","article-title":"Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?","volume":"15","author":"Bekes","year":"2016","journal-title":"Mol Cancer"},{"key":"2025100308440577000_11.2.e005968.76","first-page":"2596","article-title":"Expression levels of PTEN, HIF-1\u03b1, and VEGF as prognostic factors in ovarian cancer","volume":"21","author":"Shen","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025100308440577000_11.2.e005968.77","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025100308440577000_11.2.e005968.78","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64873-0"},{"key":"2025100308440577000_11.2.e005968.79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.1197"},{"key":"2025100308440577000_11.2.e005968.80","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.81","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0542-2","article-title":"Ccl18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling","volume":"15","author":"Lane","year":"2016","journal-title":"Mol Cancer"},{"key":"2025100308440577000_11.2.e005968.82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4375"},{"key":"2025100308440577000_11.2.e005968.83","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-3560"},{"key":"2025100308440577000_11.2.e005968.84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079769","article-title":"High MUC2 expression in ovarian cancer is inversely associated with the M1\/M2 ratio of tumor-associated macrophages and patient survival time","volume":"8","author":"He","year":"2013","journal-title":"PLoS One"},{"key":"2025100308440577000_11.2.e005968.85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038541","article-title":"BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis","volume":"7","author":"Le Page","year":"2012","journal-title":"PLoS One"},{"key":"2025100308440577000_11.2.e005968.86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63276-1","article-title":"Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients","volume":"10","author":"Macci\u00f2","year":"2020","journal-title":"Sci Rep"},{"key":"2025100308440577000_11.2.e005968.87","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0956-6","article-title":"A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome","volume":"17","author":"Reinartz","year":"2016","journal-title":"Genome Biol"},{"key":"2025100308440577000_11.2.e005968.88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100366","article-title":"Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy","volume":"10","author":"Gupta","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025100308440577000_11.2.e005968.89","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100308440577000_11.2.e005968.90","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-7-19","article-title":"A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J Ovarian Res"},{"key":"2025100308440577000_11.2.e005968.91","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.3390\/curroncol28050359","article-title":"Omental macrophagic \u201c crown-like structures \u201d are associated with poor prognosis in advanced-stage serous ovarian cancer","volume":"28","author":"Liang","year":"2021","journal-title":"Curr Oncol"},{"key":"2025100308440577000_11.2.e005968.92","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-210","article-title":"Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients","volume":"11","author":"Lane","year":"2011","journal-title":"BMC Cancer"},{"key":"2025100308440577000_11.2.e005968.93","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28335"},{"key":"2025100308440577000_11.2.e005968.94","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3892\/ijo.2012.1533","article-title":"Cytokine gene expression signature in ovarian clear cell carcinoma","volume":"41","author":"Yanaihara","year":"2012","journal-title":"Int J Oncol"},{"key":"2025100308440577000_11.2.e005968.95","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1007\/s13277-015-4066-y","article-title":"The increase of circulating PD-L1-expressing CD68 (+) macrophage in ovarian cancer","volume":"37","author":"Qu","year":"2016","journal-title":"Tumour Biol"},{"key":"2025100308440577000_11.2.e005968.96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.14748","article-title":"Ovarian cancer-specific dysregulated genes with prognostic significance: scrna-seq with bulk RNA-seq data and experimental validation","volume":"1512","author":"Liu","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"2025100308440577000_11.2.e005968.97","doi-asserted-by":"crossref","first-page":"75339","DOI":"10.18632\/oncotarget.12180","article-title":"The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization","volume":"7","author":"Finkernagel","year":"2016","journal-title":"Oncotarget"},{"key":"2025100308440577000_11.2.e005968.98","doi-asserted-by":"crossref","first-page":"23210","DOI":"10.18632\/aging.203613","article-title":"Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer","volume":"13","author":"Tan","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"2025100308440577000_11.2.e005968.99","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-017-3630-9","article-title":"Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients","volume":"18","author":"Adhikary","year":"2017","journal-title":"BMC Genomics"},{"key":"2025100308440577000_11.2.e005968.100","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA117.000400"},{"key":"2025100308440577000_11.2.e005968.101","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.434"},{"key":"2025100308440577000_11.2.e005968.102","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41551-020-0524-y","article-title":"The expanding landscape of inflammatory cells affecting cancer therapy","volume":"4","author":"Weissleder","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"2025100308440577000_11.2.e005968.103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100308440577000_11.2.e005968.104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045957","article-title":"The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100308440577000_11.2.e005968.105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (javelin ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100308440577000_11.2.e005968.106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001136","article-title":"Cxcl13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1031746","article-title":"Tumor infiltrating CD8\/CD103\/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival","volume":"13","author":"Vlaming","year":"2022","journal-title":"Front Immunol"},{"key":"2025100308440577000_11.2.e005968.108","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat Commun"},{"key":"2025100308440577000_11.2.e005968.109","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-021-00242-8","article-title":"High TGF-\u03b2 signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition","volume":"5","author":"Ni","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025100308440577000_11.2.e005968.110","first-page":"999","article-title":"Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1","volume":"3","author":"Chambers","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2025100308440577000_11.2.e005968.111","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021857","article-title":"Csf-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025100308440577000_11.2.e005968.112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100308440577000_11.2.e005968.113","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0326"},{"key":"2025100308440577000_11.2.e005968.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.016"},{"key":"2025100308440577000_11.2.e005968.115","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100308440577000_11.2.e005968.116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001153","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients","volume":"8","author":"Machiels","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.117","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10637-021-01088-4","article-title":"A phase 1a\/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors","volume":"39","author":"Falchook","year":"2021","journal-title":"Invest New Drugs"},{"key":"2025100308440577000_11.2.e005968.118","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-Stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.119","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7376"},{"key":"2025100308440577000_11.2.e005968.120","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138"},{"key":"2025100308440577000_11.2.e005968.121","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.molonc.2014.03.016","article-title":"Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers","volume":"8","author":"Moisan","year":"2014","journal-title":"Mol Oncol"},{"key":"2025100308440577000_11.2.e005968.122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Target Oncol"},{"key":"2025100308440577000_11.2.e005968.123","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2099-8"},{"key":"2025100308440577000_11.2.e005968.124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1775"},{"key":"2025100308440577000_11.2.e005968.125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial","volume":"20","author":"Vergote","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100308440577000_11.2.e005968.126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1588"},{"key":"2025100308440577000_11.2.e005968.127","doi-asserted-by":"crossref","first-page":"72147","DOI":"10.18632\/oncotarget.20046","article-title":"Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer","volume":"8","author":"Kobayashi","year":"2017","journal-title":"Oncotarget"},{"key":"2025100308440577000_11.2.e005968.128","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.29184"},{"key":"2025100308440577000_11.2.e005968.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.01.008"},{"key":"2025100308440577000_11.2.e005968.130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-20893-2","article-title":"Car-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"2025100308440577000_11.2.e005968.131","doi-asserted-by":"crossref","first-page":"109844","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep"},{"key":"2025100308440577000_11.2.e005968.132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.013"},{"key":"2025100308440577000_11.2.e005968.133","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308440577000_11.2.e005968.134","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9912188","article-title":"Toll-like receptor-based strategies for cancer immunotherapy","volume":"2021","author":"Pahlavanneshan","year":"2021","journal-title":"J Immunol Res"},{"key":"2025100308440577000_11.2.e005968.135","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0914-1"},{"key":"2025100308440577000_11.2.e005968.136","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A gynecologic oncology group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100308440577000_11.2.e005968.137","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/acs.bioconjchem.1c00139","article-title":"Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7\/8 agonist to repolarize ovarian tumors\u2019 microenvironment","volume":"32","author":"Kang","year":"2021","journal-title":"Bioconjug Chem"},{"key":"2025100308440577000_11.2.e005968.138","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704001","article-title":"TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K\/AKT\/NF-\u03bab-signaling pathway to inhibit the polarization of M2 tams","volume":"11","author":"Le","year":"2021","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.139","first-page":"622","article-title":"Targets and molecular mechanisms of triptolide in cancer therapy","volume":"26","author":"Meng","year":"2014","journal-title":"Chin J Cancer Res"},{"key":"2025100308440577000_11.2.e005968.140","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834"},{"key":"2025100308440577000_11.2.e005968.141","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554"},{"key":"2025100308440577000_11.2.e005968.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.05.011"},{"key":"2025100308440577000_11.2.e005968.143","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"2025100308440577000_11.2.e005968.144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902145116"},{"key":"2025100308440577000_11.2.e005968.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"2025100308440577000_11.2.e005968.146","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23033","article-title":"Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors","volume":"2","author":"Vonderheide","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100308440577000_11.2.e005968.147","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0805"},{"key":"2025100308440577000_11.2.e005968.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.006"},{"key":"2025100308440577000_11.2.e005968.149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0285"},{"key":"2025100308440577000_11.2.e005968.150","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24401"},{"key":"2025100308440577000_11.2.e005968.151","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"2025100308440577000_11.2.e005968.152","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3892\/mmr.2012.973","article-title":"Therapeutic effect of recombinant plasmid-encoded human interleukin-12 in tumor-bearing mice","volume":"6","author":"Sun","year":"2012","journal-title":"Mol Med Rep"},{"key":"2025100308440577000_11.2.e005968.153","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.159"},{"key":"2025100308440577000_11.2.e005968.154","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.155","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0360"},{"key":"2025100308440577000_11.2.e005968.156","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103019"},{"key":"2025100308440577000_11.2.e005968.157","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"2025100308440577000_11.2.e005968.158","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.159","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y"},{"key":"2025100308440577000_11.2.e005968.160","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008748","article-title":"Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion","volume":"5","author":"Hochreiter-Hufford","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025100308440577000_11.2.e005968.161","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","article-title":"The CD47 \u201c do\u2019n\u2019t eat me signal\u201d is highly expressed in human ovarian cancer","volume":"143","author":"Brightwell","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.162","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64398-2"},{"key":"2025100308440577000_11.2.e005968.163","doi-asserted-by":"crossref","first-page":"39021","DOI":"10.18632\/oncotarget.16547","article-title":"Cd47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2025100308440577000_11.2.e005968.164","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3892\/or.2017.5583","article-title":"Cd24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways","volume":"37","author":"Nakamura","year":"2017","journal-title":"Oncol Rep"},{"key":"2025100308440577000_11.2.e005968.165","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0"},{"key":"2025100308440577000_11.2.e005968.166","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cei\/uxab020","article-title":"Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies","volume":"209","author":"Osborn","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2025100308440577000_11.2.e005968.167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018"},{"key":"2025100308440577000_11.2.e005968.168","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"2025100308440577000_11.2.e005968.169","doi-asserted-by":"publisher","DOI":"10.1038\/nm934"},{"key":"2025100308440577000_11.2.e005968.170","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2671"},{"key":"2025100308440577000_11.2.e005968.171","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/cas.12445","article-title":"Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment","volume":"105","author":"Tanizaki","year":"2014","journal-title":"Cancer Sci"},{"key":"2025100308440577000_11.2.e005968.172","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-020-00439-w","article-title":"1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function","volume":"21","author":"Ma","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025100308440577000_11.2.e005968.173","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the clinical development of epacadostat and other indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602"},{"key":"2025100308440577000_11.2.e005968.175","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100308440577000_11.2.e005968.176","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.177","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8402","article-title":"Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses","volume":"14","author":"Odunsi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100308440577000_11.2.e005968.178","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"2025100308440577000_11.2.e005968.179","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308440577000_11.2.e005968.180","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.7.839"},{"key":"2025100308440577000_11.2.e005968.181","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"Pd-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025100308440577000_11.2.e005968.182","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0537"},{"key":"2025100308440577000_11.2.e005968.183","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","article-title":"Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced\/recurrent ovarian and uterine cancers","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025100308440577000_11.2.e005968.184","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"Parp inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2025100308440577000_11.2.e005968.185","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100308440577000_11.2.e005968.186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0968"},{"key":"2025100308440577000_11.2.e005968.187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"2025100308440577000_11.2.e005968.188","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"2025100308440577000_11.2.e005968.189","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase I study","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100308440577000_11.2.e005968.190","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0056"},{"key":"2025100308440577000_11.2.e005968.191","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153"},{"key":"2025100308440577000_11.2.e005968.192","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308440577000_11.2.e005968.193","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"Springerplus"},{"key":"2025100308440577000_11.2.e005968.194","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol"},{"key":"2025100308440577000_11.2.e005968.195","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20410"},{"key":"2025100308440577000_11.2.e005968.196","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.03.055"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:44:24Z","timestamp":1759506264000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":196,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/jitc-2022-005968"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005968","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}